PMID- 24887219
OWN - NLM
STAT- MEDLINE
DCOM- 20150330
LR  - 20211021
IS  - 2385-2070 (Electronic)
IS  - 1723-2007 (Print)
IS  - 1723-2007 (Linking)
VI  - 12
IP  - 3
DP  - 2014 Jul
TI  - The importance of antenatal prevention of RhD immunisation in the first 
      pregnancy.
PG  - 410-5
LID - 10.2450/2014.0167-13 [doi]
AB  - BACKGROUND: The aim of this study was to examine which pregnancies are associated 
      with RhD immunisation and haemolytic disease of foetus and newborn (HDFN) when 
      postnatal RhD prophylaxis is applied. MATERIAL AND METHODS: This retrospective 
      cohort study included pregnancies with RhD immunisation; each of the pregnant 
      women received anti-D immunoglobulin after delivery, miscarriage or invasive 
      antenatal diagnostic procedures. For each pregnancy we analysed the order of 
      pregnancy that caused immunisation as well as the order of the monitored 
      pregnancy and whether the anti-D antibodies caused HDFN. RESULTS: Anti-D antibody 
      was detected in 1.2% of RhD-negative pregnancies. Out of 89 monitored 
      pregnancies, 56 (63%) were immunised by the first pregnancy, 21 (24%) by the 
      second one, and 12 (13%) by subsequent pregnancies. HDFN occurred in 28 cases; 25 
      of them were the consequence of the immunisation in the first pregnancy. The most 
      severe cases of HDFN, perinatal death (n=2) and intrauterine transfusion (n=7) 
      were consequence of immunisation during the first pregnancy. Significantly more 
      cases of HDFN were caused by immunisation in the first pregnancy than by 
      immunisation in subsequent pregnancies (chi(2)=12, p<0.01). CONCLUSION: RhD 
      immunisation could be reduced in more than half cases by administering anti-D 
      immunoglobulin at the beginning of the third trimester of pregnancy, especially 
      the first pregnancy.
FAU - Dajak, Slavica
AU  - Dajak S
AD  - Department of Transfusion Medicine, Split University Hospital Centre, Split, 
      Croatia.
FAU - Roje, Damir
AU  - Roje D
AD  - Department of Obstetrics and Gynaecology, Split University Hospital Centre, 
      Split, Croatia.
FAU - Haspl, Zeljka Hundric
AU  - Haspl ZH
AD  - Croatian Institute of Transfusion Medicine, Zagreb, Croatia.
FAU - Maglic, Pera Erceg
AU  - Maglic PE
AD  - Department of Transfusion Medicine, Split University Hospital Centre, Split, 
      Croatia.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20140102
PL  - Italy
TA  - Blood Transfus
JT  - Blood transfusion = Trasfusione del sangue
JID - 101237479
RN  - 0 (Immunologic Factors)
RN  - 0 (Rh-Hr Blood-Group System)
RN  - 0 (Rho(D) Immune Globulin)
RN  - 0 (Rho(D) antigen)
SB  - IM
MH  - Adult
MH  - Erythroblastosis, Fetal/diagnosis/*prevention & control
MH  - Female
MH  - Fetomaternal Transfusion/diagnosis/*prevention & control
MH  - Humans
MH  - Immunologic Factors/*administration & dosage
MH  - Pregnancy
MH  - *Pregnancy Trimester, Third
MH  - *Rh-Hr Blood-Group System
MH  - Rho(D) Immune Globulin/*administration & dosage
PMC - PMC4111824
EDAT- 2014/06/03 06:00
MHDA- 2015/03/31 06:00
PMCR- 2014/07/01
CRDT- 2014/06/03 06:00
PHST- 2013/06/06 00:00 [received]
PHST- 2013/10/31 00:00 [accepted]
PHST- 2014/06/03 06:00 [entrez]
PHST- 2014/06/03 06:00 [pubmed]
PHST- 2015/03/31 06:00 [medline]
PHST- 2014/07/01 00:00 [pmc-release]
AID - 2014.0167-13 [pii]
AID - blt-12-410 [pii]
AID - 10.2450/2014.0167-13 [doi]
PST - ppublish
SO  - Blood Transfus. 2014 Jul;12(3):410-5. doi: 10.2450/2014.0167-13. Epub 2014 Jan 2.